[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=f3b307c9150515a3bec58103ddcc923f1940e46cca1c0105b4185ff1f35f1e57",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753288260,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 136109922,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=f3b307c9150515a3bec58103ddcc923f1940e46cca1c0105b4185ff1f35f1e57"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of […]",
    "url": "https://finnhub.io/api/news?id=6dbc183d7b7d58c46b36e5588677b7a9da6fb499a629d3350c98eac7fc3991c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753282890,
      "headline": "Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition",
      "id": 136062115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of […]",
      "url": "https://finnhub.io/api/news?id=6dbc183d7b7d58c46b36e5588677b7a9da6fb499a629d3350c98eac7fc3991c7"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Eli Lilly: “It Needs Breakthroughs in New Areas”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shed light on. While Cramer still backed the company, he did express uncertainty about its future as he stated: “What I’m thinking, as someone who owns Eli Lilly for the Charitable Trust and who wishes I owned PepsiCo, is that there might […]",
    "url": "https://finnhub.io/api/news?id=0a17951ac7efc7f365573387725281746f50a4b9e91c1061dd042070778aae84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753282527,
      "headline": "Jim Cramer on Eli Lilly: “It Needs Breakthroughs in New Areas”",
      "id": 136062116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shed light on. While Cramer still backed the company, he did express uncertainty about its future as he stated: “What I’m thinking, as someone who owns Eli Lilly for the Charitable Trust and who wishes I owned PepsiCo, is that there might […]",
      "url": "https://finnhub.io/api/news?id=0a17951ac7efc7f365573387725281746f50a4b9e91c1061dd042070778aae84"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says “We Should be in ConocoPhillips”",
    "summary": "ConocoPhillips (NYSE:COP) is one of the stocks that Jim Cramer shed light on. When a caller asked about the company during the lightning round, Cramer commented: “All right. Buy COP. Let me tell you, I just told Jeff Marks, my partner for the club, that we’re in the wrong one now. Coterra is not delivering. […]",
    "url": "https://finnhub.io/api/news?id=a206bf66976e95e934f9f10cd41e0ba0c03cbe17a0345292526c7f8cdd1cb705",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753282515,
      "headline": "Jim Cramer Says “We Should be in ConocoPhillips”",
      "id": 136062117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ConocoPhillips (NYSE:COP) is one of the stocks that Jim Cramer shed light on. When a caller asked about the company during the lightning round, Cramer commented: “All right. Buy COP. Let me tell you, I just told Jeff Marks, my partner for the club, that we’re in the wrong one now. Coterra is not delivering. […]",
      "url": "https://finnhub.io/api/news?id=a206bf66976e95e934f9f10cd41e0ba0c03cbe17a0345292526c7f8cdd1cb705"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says He Does Not Want Novo Nordisk Due to Tariffs",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and Cramer replied: “I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about tariffs on foreign drugs versus Eli Lilly, […]",
    "url": "https://finnhub.io/api/news?id=a4ac0a0a1099c53e0a29ca106d30c905029a01a3ed9621e788557029780ea3a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753282507,
      "headline": "Jim Cramer Says He Does Not Want Novo Nordisk Due to Tariffs",
      "id": 136045430,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and Cramer replied: “I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about tariffs on foreign drugs versus Eli Lilly, […]",
      "url": "https://finnhub.io/api/news?id=a4ac0a0a1099c53e0a29ca106d30c905029a01a3ed9621e788557029780ea3a8"
    }
  },
  {
    "ts": null,
    "headline": "India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says",
    "summary": "HYDERABAD (Reuters) -Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday.  Drugmakers are racing to get a share of the global obesity drug market, expected to generate around $150 billion in sales by the early 2030s, after Denmark-based Novo and its U.S. rival Eli Lilly  saw extraordinary demand for their medicines.  Dr Reddy's initially plans to launch the generic version of semaglutide - the active ingredient of Novo's Wegovy and diabetes medicine Ozempic - in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said.",
    "url": "https://finnhub.io/api/news?id=4d6496ba3aafe38ef860b5617bfb62561f86cf763e3229426bba7cd22d1e2351",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753280834,
      "headline": "India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says",
      "id": 136061443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "HYDERABAD (Reuters) -Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday.  Drugmakers are racing to get a share of the global obesity drug market, expected to generate around $150 billion in sales by the early 2030s, after Denmark-based Novo and its U.S. rival Eli Lilly  saw extraordinary demand for their medicines.  Dr Reddy's initially plans to launch the generic version of semaglutide - the active ingredient of Novo's Wegovy and diabetes medicine Ozempic - in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said.",
      "url": "https://finnhub.io/api/news?id=4d6496ba3aafe38ef860b5617bfb62561f86cf763e3229426bba7cd22d1e2351"
    }
  },
  {
    "ts": null,
    "headline": "Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs",
    "summary": "Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ingredients from China, Reuters reported recently. Reuters cited a 44% monthly increase in January in shipments of tirzepatide and semaglutide from Chinese suppliers not registered with the U.S. Food and Drug Administration, according to data from the Partnership for Safe Medicines. The gray market",
    "url": "https://finnhub.io/api/news?id=254d49b78534fcb5954f566c25bd0105ec46fd2ea2b9fd5142243efb36926bd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753280100,
      "headline": "Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs",
      "id": 136045432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ingredients from China, Reuters reported recently. Reuters cited a 44% monthly increase in January in shipments of tirzepatide and semaglutide from Chinese suppliers not registered with the U.S. Food and Drug Administration, according to data from the Partnership for Safe Medicines. The gray market",
      "url": "https://finnhub.io/api/news?id=254d49b78534fcb5954f566c25bd0105ec46fd2ea2b9fd5142243efb36926bd5"
    }
  },
  {
    "ts": null,
    "headline": "Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?",
    "summary": "AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.",
    "url": "https://finnhub.io/api/news?id=269ef53d452cc72ad46dd759ed1134393bf4197c408e722f6b54a619e5c5b2da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753278420,
      "headline": "Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?",
      "id": 136045433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.",
      "url": "https://finnhub.io/api/news?id=269ef53d452cc72ad46dd759ed1134393bf4197c408e722f6b54a619e5c5b2da"
    }
  },
  {
    "ts": null,
    "headline": "Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results",
    "summary": "Shares of Abivax hit the stratosphere Wednesday after the firm unveiled \"potentially disruptive\" results for its ulcerative colitis drug.",
    "url": "https://finnhub.io/api/news?id=740c5c3502a0118d2c436b26dd81a40b6f26e2b2e383432128c1d36022ac9e97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753276507,
      "headline": "Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results",
      "id": 136044154,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Abivax hit the stratosphere Wednesday after the firm unveiled \"potentially disruptive\" results for its ulcerative colitis drug.",
      "url": "https://finnhub.io/api/news?id=740c5c3502a0118d2c436b26dd81a40b6f26e2b2e383432128c1d36022ac9e97"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Preview: What to Expect From Eli Lilly's Report",
    "summary": "Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.",
    "url": "https://finnhub.io/api/news?id=9e6d8b25decef50ce8cb3a999152a66f1ef37c109a1cd24e6289a8e06299ca0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753271204,
      "headline": "Earnings Preview: What to Expect From Eli Lilly's Report",
      "id": 136044155,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.",
      "url": "https://finnhub.io/api/news?id=9e6d8b25decef50ce8cb3a999152a66f1ef37c109a1cd24e6289a8e06299ca0e"
    }
  },
  {
    "ts": null,
    "headline": "Roche’s Elecsys pTau181 test gains CE Mark to rule out Alzheimer’s",
    "summary": "A multi-centre, prospective trial involving 787 subjects across Australia, Europe, and the US formed the basis for the CE Mark.",
    "url": "https://finnhub.io/api/news?id=902ccfe7653edf15afdabdcfa207c7db33060ae27bf87bd3f163368dd97d43d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753269965,
      "headline": "Roche’s Elecsys pTau181 test gains CE Mark to rule out Alzheimer’s",
      "id": 136044156,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A multi-centre, prospective trial involving 787 subjects across Australia, Europe, and the US formed the basis for the CE Mark.",
      "url": "https://finnhub.io/api/news?id=902ccfe7653edf15afdabdcfa207c7db33060ae27bf87bd3f163368dd97d43d8"
    }
  },
  {
    "ts": null,
    "headline": "The protein boom is only beginning",
    "summary": "Food and beverage companies are scrambling to deliver the macronutrient of the moment.",
    "url": "https://finnhub.io/api/news?id=3510deadbb3ece604059c04707cd9ca41312246e0f3317821225c4f88427fad1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753264711,
      "headline": "The protein boom is only beginning",
      "id": 136040328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Food and beverage companies are scrambling to deliver the macronutrient of the moment.",
      "url": "https://finnhub.io/api/news?id=3510deadbb3ece604059c04707cd9ca41312246e0f3317821225c4f88427fad1"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: The Market Hasn't Given It Enough Respect",
    "summary": "Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for long-term investors to capitalize now.",
    "url": "https://finnhub.io/api/news?id=c1665b1657ad75c066f1a28c2e2e2e39c78b26460ac2dfc9acef3eb7ed68a685",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753262520,
      "headline": "Novo Nordisk: The Market Hasn't Given It Enough Respect",
      "id": 136042379,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305433/image_2158305433.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for long-term investors to capitalize now.",
      "url": "https://finnhub.io/api/news?id=c1665b1657ad75c066f1a28c2e2e2e39c78b26460ac2dfc9acef3eb7ed68a685"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Pain 8 Major Market Forecast Report 2025-2034 | Opioids and Non-Opioids Drive Innovations, Medical Cannabis Emerges as Alternative",
    "summary": "The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6.10%. Growth is driven by rising cancer cases and advancements in pain management, including medical cannabis. Key players include Eli Lilly, Pfizer, and Johnson & Johnson. Cancer Pain Market Cancer Pain Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Pain Market Report and Forecast 2025-2034\" report has been added to ResearchAndMarkets.com's offering.The canc",
    "url": "https://finnhub.io/api/news?id=cd387d7651a3df8bb96f38bcdf02db1a89535f3ab4083bcf6a56127b0a5f35ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753258140,
      "headline": "Cancer Pain 8 Major Market Forecast Report 2025-2034 | Opioids and Non-Opioids Drive Innovations, Medical Cannabis Emerges as Alternative",
      "id": 136039626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6.10%. Growth is driven by rising cancer cases and advancements in pain management, including medical cannabis. Key players include Eli Lilly, Pfizer, and Johnson & Johnson. Cancer Pain Market Cancer Pain Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Pain Market Report and Forecast 2025-2034\" report has been added to ResearchAndMarkets.com's offering.The canc",
      "url": "https://finnhub.io/api/news?id=cd387d7651a3df8bb96f38bcdf02db1a89535f3ab4083bcf6a56127b0a5f35ba"
    }
  },
  {
    "ts": null,
    "headline": "Baron Health Care Fund Q2 2025 Shareholder Letter",
    "summary": "Baron Health Care Fund Q2 2025 Shareholder Letter",
    "url": "https://finnhub.io/api/news?id=2a38b587e95b4466e191dc0d0785bc071c09227e082ab14e1840dabaef7d2da8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753254780,
      "headline": "Baron Health Care Fund Q2 2025 Shareholder Letter",
      "id": 136040471,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2a38b587e95b4466e191dc0d0785bc071c09227e082ab14e1840dabaef7d2da8"
    }
  },
  {
    "ts": null,
    "headline": "The Ithaka Group Q2 2025 Commentary",
    "summary": "Amid Q2 chaos, Ithaka outperformed by backing resilient growth stocks like Nvidia and Microsoft. See how theyâre navigating volatility with conviction.",
    "url": "https://finnhub.io/api/news?id=3caae37041366c8c12b5eb9480c8abd969e88467ff6b9daffab1b0dd3952a7ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753251000,
      "headline": "The Ithaka Group Q2 2025 Commentary",
      "id": 136039981,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2210645043/image_2210645043.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Amid Q2 chaos, Ithaka outperformed by backing resilient growth stocks like Nvidia and Microsoft. See how theyâre navigating volatility with conviction.",
      "url": "https://finnhub.io/api/news?id=3caae37041366c8c12b5eb9480c8abd969e88467ff6b9daffab1b0dd3952a7ca"
    }
  },
  {
    "ts": null,
    "headline": "Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease",
    "summary": "Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology.The minimally invasive, blood-based test can serve as a rule out for Alzheimer’s pathology, reducing the need for confirmatory testing with a negative result.Data from clinical study supports use in primary care for people with varying signs of cognitive decline. Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for",
    "url": "https://finnhub.io/api/news?id=753ea4f4f89b2a5b2b6ac53f877602fccddc10365ab19537f85e0a376c4f5b3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753247400,
      "headline": "Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease",
      "id": 136038195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology.The minimally invasive, blood-based test can serve as a rule out for Alzheimer’s pathology, reducing the need for confirmatory testing with a negative result.Data from clinical study supports use in primary care for people with varying signs of cognitive decline. Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for",
      "url": "https://finnhub.io/api/news?id=753ea4f4f89b2a5b2b6ac53f877602fccddc10365ab19537f85e0a376c4f5b3e"
    }
  }
]